ArticlePLoS neglected tropical diseases2016
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Review
- Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model.PLoS neglected tropical diseases · 2024Article
- Mycobacterium ulcerans culture results according to duration of prior antibiotic treatment: A cohort study.PloS one · 2023Article
- Determination of Bioenergetic Parameters in Mycobacterium ulcerans.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
- Toward a Single-Dose Cure for Buruli Ulcer.Antimicrobial agents and chemotherapy · 2020Article
- Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.PLoS neglected tropical diseases · 2020Article
- Pharmacologic management ofExpert review of clinical pharmacology · 2020Review
- Global Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets.Emerging infectious diseases · 2019Article
- High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.Antimicrobial agents and chemotherapy · 2019Article
- The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.Nature communications · 2019Article
- Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.PLoS neglected tropical diseases · 2019Article
- Treatment for Buruli ulcer: the long and winding road to antimicrobials-first.The Cochrane database of systematic reviews · 2018Article
- Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.PLoS neglected tropical diseases · 2018Article
- Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.Current infectious disease reports · 2018Review
- Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.Clinical microbiology reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of Buruli ulcer (BU) that is caused by Mycobacterium ulcerans, is currently based on a daily administration of rifampin and streptomycin (RIF-STR). A fully oral intermittent regimen would greatly simplify its treatment on the field. METHODOLOGY/PRINCIPAL
findingsThe objective of this study was to assess the bactericidal and sterilizing activities of intermittent oral regimens in a murine model of established M. ulcerans infection. Regimens combining rifapentine (RFP 20 mg/kg) with either moxifloxacin (MXF 200 mg/kg), clarithromycin (CLR 100 mg/kg) or bedaquiline (BDQ 25 mg/kg) were administrated twice (2/7) or three (only for RFP-CLR 3/7) times weekly during 8 weeks. The bactericidal but also the sterilizing activities of these four intermittent oral regimens were at least as good as those obtained with control weekdays regimens, i.e. RFP-CLR 5/7 or RIF-STR 5/7. A single mouse from the RFP-MFX 2/7 group had culture-positive relapse at the end of the 28 weeks following treatment completion among the 157 mice treated with one of the four intermittent regimens (40 RFP-CLR 2/7, 39 RFP-CLR 3/7, 39 RFP-MXF 2/7, 39 RFP-BDQ 2/7). CONCLUSIONS/SIGNIFICANCE: These results open the door for a fully intermittent oral drug regimen for BU treatment avoiding intramuscular injections and facilitating supervision by health care workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.